Biopharmaceutical giant GSK announced a site expansion at its Marietta, Pennsylvania site, where it will build a multipurpose manufacturing facility to produce sterile liquid vaccines and other ...

This website (the “Site”) is operated by Informa Connect, a trading division of the Informa Group. The parent company of the Informa Group is Informa PLC. Informa Connect (“Informa Connect”, “we” or ...

Martin Smith, PhD CTO, Pall Corporation Thank you for taking the time to view our supplement, which has been driven by our desire to share actionable knowledge in a convenient format as well as to act ...

Multichain protein biotherapeutics such as bispecific molecules have been developed to treat cancer, neurological and ophthalmic disorders, and autoimmune and inflammatory diseases. Early successes ...

Pluri signed a deal worth $4.2 million with the US National Institute of Allergy and Infectious Diseases (NIAID), a division of NIH, in 2023. $1.4 million of the total amount has been dedicated by NIH ...

The firms will co-commercialize the products globally, except for MK-6070 in Japan where Merck (known as MSD outside of the US and Canada) will retain the exclusive rights. Merck will also be solely ...

First reported by Reuters, this facility will potentially be used as a fill/finish plant to manufacture injection pens for Novo’s star weight loss drugs Wegovy and Ozempic (semaglutide). Confirming ...

Contract development manufacturing organization (CDMO) MilliporeSigma – the life sciences division of Merck KGaA – will manufacture GMP-compliant dry powder and liquid CCM to support a wide range of ...

Glucagon-like peptide-1 (GLP-1) drugs for diabetes and weight loss are emerging as the latest blockbuster pharmaceuticals. Like messenger RNA (mRNA) gaining recognition during the pandemic, the ...

The buildout of its $1.5 billion facility will establish the Anglo-Swedish drugmaker’s first manufacturing presence in Singapore. Additionally, it will be AstraZeneca’s first ADC plant to produce the ...

Sanofi will build a €1 billion ($1.1 billion) mAb production facility in Vitry-sur-Seine, while it invests €100 million to bolster capacity at its Le Trait site in Normandy and invests €10 million at ...

Properly scaling from small-scale bioreactors to larger-scale bioreactors for intensified processes is highly dependent on maintaining mixing, oxygenation, nutrient, and process control. To be able to ...